Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PLAU | P00749 | 1/20 | 0.62 |
| ▸ | ELANE | P08246 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424713 | 0.87 | NPC1 (0.62) | RAB9ANPC1ALDH1A1EGFRL3MBTL1 | |
| SCHEMBL5169062 | 0.86 | ALDH1A1 (0.62) | RAB9ANPC1HTTALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL14812337 | 0.82 | CNR2 (0.54) | RAB9ANPC1ALDH1A1CNR2EGFR | |
| SCHEMBL14821325 | 0.81 | ITGB3 (0.59) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14812072 | 0.81 | EPHX2 (0.65) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL14812031 | 0.80 | ITGB3 (0.58) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7498475 | 0.79 | RAB9A (0.63) | RAB9ANPC1HTTALDH1A1MAPT | |
| SCHEMBL14811905 | 0.79 | EPHX2 (0.54) | RAB9ANPC1HTTALDH1A1MAPT | |
| SCHEMBL4928502 | 0.79 | HTT (0.73) | RAB9ANPC1HTTALDH1A1MAPT | |
| SCHEMBL5862101 | 0.79 | NPC1 (1.00) | RAB9ANPC1HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045726-A1 | Spirolactams and Their Synthesis | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-21 | — | — | US | disclosed |
| US-7291728-B2 | Spirolactams and their synthesis | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2007-11-06 | — | — | US | disclosed |
| EP-1771410-A1 | SPIROLACTAMS AND THEIR SYNTHESIS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005108356-A1 | SPIROLACTAMS AND THEIR SYNTHESIS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-17 | — | — | WO | disclosed |
| EP-1595865-A1 | New spirolactams and their synthesis | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-16 | — | — | EP | disclosed |
| US-20050250759-A1 | Spirolactams and their synthesis | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045726-A1 | Spirolactams and Their Synthesis | VKORC1, VKORC1L1, DHPS | RAB9A 3664/4885NPC1 2503/4885HTT 4166/4885 |
| US-20050250759-A1 | Spirolactams and their synthesis | VKORC1, DHPS, SRI | RAB9A 2631/4885NPC1 1478/4885HTT 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.